Two probiotic strains have Grade A evidence from the World Gastroenterology Organisation specifically for antibiotic-associated gut recovery: Saccharomyces boulardii and Lactobacillus rhamnosus GG. Most probiotics sold in Indian pharmacies contain neither at effective doses, and virtually all use standard capsule formats that lose 90% or more of viable bacteria to stomach acid before reaching the intestine. Strain selection and delivery format both matter. Getting one right without the other is not sufficient.
The problem with what is available in India
Walk into any chemist in India and ask for something to take after antibiotics. You will be handed one of several well-known sachet or capsule products. The pharmacist will likely say these are the standard recommendation and they have been giving them out for years. None of this is dishonest. The products exist, they contain live bacteria, and some of them have been on the market for decades.
The issue is not that these products are fraudulent. The issue is that they were not designed for the specific clinical context of post-antibiotic gut recovery. They were designed for general gut health maintenance, which is a meaningfully different problem. The strains, doses, and delivery formats appropriate for maintaining a healthy microbiome in a person who has not just taken a broad-spectrum antibiotic are not the same as those shown to work in antibiotic-associated gut disruption trials.
There are three specific gaps between what is available and what the evidence requires.
Gap 1: Wrong strains or absent strains
The two strains with the strongest specific evidence for post-antibiotic recovery, Saccharomyces boulardii and Lactobacillus rhamnosus GG (ATCC 53103), are either absent from most Indian pharmacy products or present in very low concentrations. The strains that dominate Indian pharmacy probiotics, primarily various Lactobacillus acidophilus and Bacillus clausii combinations, have good general gut health evidence but considerably weaker specific evidence for the post-antibiotic recovery context.
Strain specificity matters in probiotics more than in most nutraceutical categories. Evidence for one Lactobacillus strain does not transfer automatically to another. The evidence for LGG specifically is built on studies using the ATCC 53103 strain designation. A product containing a different Lactobacillus rhamnosus strain is not the same thing, even if the species name is identical.
Gap 2: Doses too low
The clinical trials that demonstrate real outcomes for post-antibiotic recovery consistently use doses in the range of 5 to 10 billion CFU per day for bacterial strains and 250 to 500mg (equivalent to roughly 5 billion CFU) for S. boulardii. Many pharmacy products contain 1 to 2 billion CFU per sachet, which is below the threshold shown to produce consistent outcomes in the literature. A lower dose is not simply a weaker version of the same effect. Below certain thresholds, there may be no meaningful clinical effect at all.
Gap 3: Delivery format that does not reach the intestine
This is the most significant gap and the least discussed. The stomach is an acid environment with a pH of 1.5 to 3.5 during active digestion. Standard gelatin and cellulose capsules dissolve within minutes in this environment. Sachets dissolve even faster. The probiotic bacteria are then exposed to gastric acid, which kills the vast majority before they reach the small intestine, which is where they need to be to have any effect.
Studies measuring the actual intestinal delivery of standard pharmacy probiotic formats consistently show 90% or greater CFU attrition before the bacteria exit the stomach. This is not a fringe finding. It is why the clinical trials that show real outcomes use delayed release delivery formats, specifically pH-sensitive capsules that remain intact through gastric acid and dissolve only at the higher pH of the small intestine.
We have covered this in detail in a separate article: why most probiotics never actually reach your gut.
More bacteria on the label does not mean more bacteria reaching your intestine
A sachet listing 10 billion CFU on the label that dissolves in stomach acid delivers fewer viable bacteria to the intestine than a delayed release capsule with 5 billion CFU on the label. The CFU count on the label describes what is in the product at manufacture, not what survives the journey. Delivery format determines what actually arrives.
The two strains that actually work
The following is grounded entirely in the clinical literature, specifically in the World Gastroenterology Organisation 2023 Global Guidelines on Probiotics and Prebiotics, which represent the most current and comprehensive synthesis of the clinical evidence.
A probiotic yeast, not a bacterium. Antibacterial antibiotics cannot kill it, which is why it is uniquely effective during and immediately after antibiotic courses. A 2017 Cochrane meta-analysis of 82 randomised controlled trials found it reduces the risk of antibiotic-associated diarrhoea by approximately 53%. The only probiotic to achieve this level of evidence specifically in the post-antibiotic context.
WGO Grade A EvidenceThe most studied probiotic bacterium in the world. Exceptional adhesion to intestinal epithelium, production of compounds that inhibit pathogenic overgrowth, and specific evidence for restoring gut flora after antibiotic courses. The strain designation ATCC 53103 matters. Evidence for LGG does not transfer to other rhamnosus strains.
WGO Grade A EvidenceBeyond these two, Bifidobacterium lactis Bl-04 has solid evidence for restoring species diversity and short-chain fatty acid production post-antibiotic. It works best in combination with LGG rather than as a standalone. You can read the full evidence breakdown in our B. lactis Bl-04 article.
How Indian pharmacy probiotics compare
This is not a criticism of the companies that make these products. They serve a different purpose. It is a clinical comparison to help you understand the gap between general wellness probiotics and post-antibiotic recovery support.
| Factor | Pharmacy Probiotics (India) | Post-Antibiotic Evidence Standard |
|---|---|---|
| Primary strains | L. acidophilus, Bacillus clausii, various | S. boulardii + LGG ATCC 53103 |
| CFU dose | 1 to 3 billion CFU typical | 5 to 10 billion CFU per strain |
| Delivery format | Standard sachet or gelatin capsule | Delayed release HPMC capsule |
| Stomach acid survival | ✗ 90%+ CFU loss typical | ✓ Intact through gastric pH |
| WGO Grade A evidence for AAD | ✗ Not typically | ✓ Both primary strains |
| Mucosal repair support | ✗ Not addressed | ✓ Zinc Carnosine |
| Epithelial fuel | ✗ Not addressed | ✓ L-Glutamine |
| Designed for post-antibiotic use | ∼ General gut wellness | ✓ Specifically |
When to start and how long to take
Timing matters considerably more than most people realise. The 14 days immediately after finishing an antibiotic course are the window when the gut microbiome is most disrupted and most receptive to recovery intervention. The bacterial ecology of the gut is actively reorganising during this period. Whether beneficial or opportunistic bacteria establish themselves in the vacant niches depends partly on what support the gut receives in this window.
Starting probiotics two to three weeks after finishing a course, when symptoms have already begun resolving on their own, misses the period of highest potential impact. Starting on the day the course ends, or the day after at most, gives recovery support the best possible opportunity to influence the trajectory of the microbiome reorganisation.
S. boulardii can be started while the course is still ongoing, because it is a yeast and antibiotics do not kill it. If you have a few days remaining on your antibiotic course and you have access to S. boulardii, starting immediately rather than waiting for the last dose is clinically appropriate.
14 days is the evidence-supported recovery window
The 14-day duration of the Aegis Protocol is not arbitrary. The clinical trials showing the strongest outcomes for structured post-antibiotic recovery support use 14-day intervention periods. This aligns with the biological timeline of early microbiome reorganisation. Continuing beyond 14 days provides diminishing marginal benefit as the microbiome begins to self-regulate. Stopping at 7 days misses the consolidation phase where the ecological gains from the first week are reinforced.
What to actually look for when choosing a probiotic after antibiotics
If you are buying a probiotic after finishing an antibiotic course, here is the practical checklist based on what the evidence requires.
Check the strain designation, not just the species name
The label should say Lactobacillus rhamnosus GG or ATCC 53103, not just Lactobacillus rhamnosus. It should say Saccharomyces boulardii CNCM I-745, not just Saccharomyces boulardii. Products that list only the species name without the strain designation cannot be confirmed to be the specific strains studied in the clinical trials. This matters because evidence is strain-specific, not species-specific.
Check the dose
The label should show at least 5 billion CFU for S. boulardii and at least 10 billion CFU for LGG. If the label shows a combined CFU count for multiple strains without showing individual strain doses, you cannot confirm any individual strain meets the clinical threshold. A product listing 10 billion CFU total across five strains may have 2 billion of each, which is below the effective threshold for each.
Check the capsule format
Standard gelatin capsules, cellulose capsules, and sachets all dissolve in stomach acid. Delayed release formats are described on labels as HPMC delayed release, enteric coated, pH-sensitive, or DRcap. If the packaging does not specify a delayed release or enteric coated format, assume it is standard and account for the significant CFU attrition before the intestine.
Check for mucosal repair support
Probiotics address the microbial disruption from antibiotics. They do not directly address the structural damage to the gut lining. Zinc Carnosine addresses the mucosal damage directly and L-Glutamine provides the cellular fuel for gut lining repair. A probiotic-only approach, however well-chosen the strains, addresses only the bacterial component of post-antibiotic gut disruption.
What about curd and fermented foods
Eating curd daily after an antibiotic course is genuinely beneficial and should be part of recovery. Curd provides live Lactobacillus cultures, supports microbial diversity, and is well tolerated even when the gut is disrupted. It is not a substitute for targeted supplementation, but it is a meaningful complement to it.
The limitations of curd for post-antibiotic recovery are the same as for standard pharmacy probiotics: the bacterial counts are lower than clinical doses, the strains are general wellness strains rather than post-antibiotic specific strains, and the bacteria are exposed to stomach acid without protection. We have covered this in full in our curd article.
Eat the curd. Also address the gap that curd cannot fill.